Antibodies binding to ceacam5
By designing antibodies with specific heavy and light chain variable region sequences, the problem of poor expression of humanized CEACAM5 antibodies in mammalian expression systems was solved, achieving efficient binding of CEACAM5 and reducing immunogenicity, making it suitable for cancer treatment.
CN122422356APending Publication Date: 2026-07-17F HOFFMANN LA ROCHE & CO AG
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- F HOFFMANN LA ROCHE & CO AG
- Filing Date
- 2024-12-18
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing humanized CEACAM5 antibodies exhibit poor expression characteristics in common mammalian expression systems, limiting their application as therapeutic agents.
Method used
A novel antibody has been developed, containing specific heavy and light chain variable region sequences, exhibiting good expression characteristics, binding affinity, and specificity. It is suitable for binding to CEACAM5 and can further bind to CD3 to form a multispecific antibody.
Benefits of technology
This study achieved good expression and efficient binding of the antibody to CEACAM5 in a mammalian expression system, reduced predicted immunogenicity, and improved therapeutic efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
本发明总体上涉及与 CEACAM5 结合的抗体。此外，本发明涉及编码此类抗体的多核苷酸，以及包含此类多核苷酸的载体和宿主细胞。本发明进一步涉及用于产生所述抗体的方法，以及涉及在疾病的治疗中使用所述抗体的方法。
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
CS176501B1
Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
EP0404097A2
RNA-coded antibody
EP2101823B1
Glycoprotein compositions
US20030157108A1
Antibody composition which specifically binds to CD20
US20040093621A1